The Bioequivalence Study of Fixed-dose Combination of Vildagliptin and Metformin HCI 50/1000 mg FCT Under Fed Conditions
Condition(s):Healthy VolunteerLast Updated:February 7, 2024Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):Healthy VolunteerLast Updated:February 7, 2024Not yet recruiting
Condition(s):Diabetes Mellitus, Type 2Last Updated:November 3, 2016Completed
Condition(s):Healthy SubjectsLast Updated:February 8, 2024Not yet recruiting
Condition(s):Type 2 DiabetesLast Updated:January 19, 2024Recruiting
Condition(s):1- Microvascular Function; 2-oxidative Stress; 3-inflammationLast Updated:May 31, 2017Completed
Condition(s):Diabetes; HypoglycemiaLast Updated:September 25, 2012Completed
Condition(s):Type 1 Diabetes; Insulin Dependent Diabetes; Juvenile Onset Diabetes Mellitus; Autoimmune DiabetesLast Updated:May 14, 2014Unknown status
Condition(s):DiabetesLast Updated:September 30, 2014Completed
Condition(s):Type 2 Diabetes MellitusLast Updated:August 30, 2013Completed
Condition(s):SDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV InhibitorsLast Updated:September 2, 2020Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.